157 filings
Page 4 of 8
424B5
pda1ivlt58gsw72fxl
6 Aug 21
Prospectus supplement for primary offering
4:34pm
8-K
zqu0ua419a2zr
6 Aug 21
Entry into a Material Definitive Agreement
4:09pm
424B5
b2bnbx y5
6 Aug 21
Prospectus supplement for primary offering
4:05pm
8-K
9lhhg5g9qdk47pe4v
5 Aug 21
Arvinas Reports Second Quarter 2021 Financial Results and Provides Corporate Update
4:02pm
8-K
op46iqav v2
22 Jul 21
Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTACĀ® Protein
7:30am
8-K
kb98ojc an6s
9 Jun 21
Submission of Matters to a Vote of Security Holders
4:01pm
CT ORDER
tq8vyg6az5zxx 6t6
26 May 21
Confidential treatment order
12:00am
CT ORDER
1c4e0faf3f2jwg3tig
26 May 21
Confidential treatment order
12:00am
8-K
0n7 qwwh0vn
4 May 21
Arvinas Reports First Quarter 2021 Financial Results and Provides Corporate Update
4:02pm
DEFA14A
no4hubzms9
26 Apr 21
Additional proxy soliciting materials
4:22pm
8-K
a4paje 3ixl
1 Mar 21
Arvinas Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
4:03pm
S-8
qnf5x8xssyy5 dqu0a
1 Mar 21
Registration of securities for employees
12:00am
8-K
6rpcl8fxygg
6 Jan 21
Entry into a Material Definitive Agreement
4:31pm
8-K
qqx15m8qyg
18 Dec 20
Arvinas, Inc. Announces Pricing of $400 Million Public Offering of Common Stock
6:30am
424B5
q6wwe48
16 Dec 20
Prospectus supplement for primary offering
4:01pm
424B5
v6ld7m gr
14 Dec 20
Prospectus supplement for primary offering
4:48pm